UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS employer |
of incorporation) |
| File Number) |
| identification number) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant's telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbol(s) |
| Name of Each Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On May 11, 2023, Palatin Technologies, Inc. issued a press release announcing a conference call and live audio webcast to be held May 16, 2023. A copy of this press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PALATIN TECHNOLOGIES, INC. |
| |
|
|
|
|
Date: May 12, 2023 | By: | /s/ Stephen T. Wills |
|
|
| Stephen T. Wills, CPA, MST |
|
|
| Executive Vice President, Chief Financial Officer and Chief Operating Officer |
|
| 3 |
EXHIBIT INDEX
| 4 |
EXHIBIT 99.1
Palatin to Report Third Quarter Fiscal Year 2023 Results;
Teleconference and Webcast to be held on May 16, 2023
CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
| Q3 Fiscal Year 2023 Results Press Release |
| 05/16/2023 at 7:30 a.m. ET |
|
|
|
|
| Q3 Fiscal Year 2023 Conference Call-Live |
| 05/16/2023 at 11:00 a.m. ET |
| US Toll Free Dial-In Number: |
| 1-888-506-0062 |
| International Dial-In Number: |
| 1-973-528-0011 |
| Participant Access Code: |
| 555988 |
|
|
|
|
| Q3 Fiscal Year 2023 Conference Call-Replay |
| 05/16/2023-05/30/2023 |
| US Toll Free Dial-In Number: |
| 1-877-481-4010 |
| International Dial-In Number: |
| 1-919-882-2331 |
| Participant Access Code: |
| 48459 |
The audio webcast and replay can be accessed by logging on to the “Investors-Webcasts” section of Palatin’s website at http://www.palatin.com or by accessing this link.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
| Palatin Investor Inquiries: | Palatin Media Inquiries: |
| Stephen T. Wills, CPA, MST | Paul Arndt, MBA, LifeSci Advisors, LLC |
| Chief Operating Officer / Chief Financial Officer | Managing Director |
| Tel: (609) 495-2200 / info@palatin.com | Tel: (646) 597-6992 / Paul@LifeSciAdvisors.com |
###
Cover |
May 11, 2023 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | Palatin Technologies, Inc. |
| Entity Central Index Key | 0000911216 |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Emerging Growth Company | false |
| Document Period End Date | May 11, 2023 |
| Entity Incorporation State Country Code | DE |
| Entity Tax Identification Number | 95-4078884 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity File Number | 001-15543 |
| Entity Address Address Line 1 | 4B Cedar Brook Drive |
| Entity Address City Or Town | Cranbury |
| Entity Address State Or Province | NJ |
| Entity Address Postal Zip Code | 08512 |
| City Area Code | 609 |
| Local Phone Number | 495-2200 |
| Security 12b Title | Common Stock |
| Trading Symbol | PTN |
| Security Exchange Name | NYSE |